AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
With AI advancements upending the role of senior executives, the question is what the C-suite transformation should look like ...
Mandated DNS blocking is the wrong tool for public policy enforcement. The DNS exists to make the Internet usable, not to serve as a mechanism of control.
These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. In other recent news, Recursion Pharmaceuticals reported its second-quarter 2025 earnings, highlighting ...
Recursion Pharmaceuticals (NASDAQ:RXRX), a $2.3 billion market cap biotech company currently trading at $5.31, saw Chief Executive Officer Christopher Gibson sell 100,000 shares of Class A Common ...
The shares were sold at a price of $5.64, for a total value of $21,369. InvestingPro analysis reveals 10+ additional insights about Recursion’s financial health and valuation, available in the ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a $2.48 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 617,875 shares of Class A Common Stock on August 11, 2025 ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a $2.48 billion market cap biotech company, saw Chief Executive Officer Christopher Gibson sell 617,875 shares of Class A Common Stock on August 11, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback